Active, not recruitingPHASE1, PHASE2NCT02158091

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Matthew Davids, MD
Dana-Farber Cancer Institute
Intervention
IPI-145(drug)
Enrollment
32 enrolled
Eligibility
18-65 years · All sexes
Timeline
20142026

Study locations (2)

Collaborators

Secura Bio, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02158091 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials